Markers of inflammation in relation to long-term cardiovascular mortality in patients with lower-extremity peripheral arterial disease

International Journal of Cardiology

Volumn 160, Issue 2, 2012, Pages 89-94

  Urbonaviciene, Grazina ^a   Frystyk, Jan ^b   Flyvbjerg, Allan ^b   Urbonavicius, Sigitas ^a   Henneberg, Eskild W ^a   Lindholt, Jes S ^a  

^a VIBORG HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Defensin; Cardiovascular; Inflammatory markers; Peripheral arterial disease

Indexed keywords

ALPHA DEFENSIN; C REACTIVE PROTEIN;

ACCURACY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CRITICAL LIMB ISCHEMIA; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; LEG DISEASE; LETHALITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

AGED; ALPHA-DEFENSINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INFLAMMATION; LEG; MALE; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84866025706     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.03.030     Document Type: Article

References (36)

1. N.W. Shammas Epidemiology, classification, and modifiable risk factors of peripheral arterial disease Vasc Health Risk Manag 3 2 2007 229 234
2. Y.W. Chi, and M.R. Jaff Optimal risk factor modification and medical management of the patient with peripheral arterial disease Catheter Cardiovasc Interv 71 4 2008 475 489
3. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 7121 2006 860 867
4. L.F. Van Gaal, I.L. Mertens, and C.E. De Block Mechanisms linking obesity with cardiovascular disease Nature 444 7121 2006 875 880
5. T. Naruko, M. Ueda, and K. Haze Neutrophil infiltration of culprit lesions in acute coronary syndromes Circulation 106 23 2002 2894 2900
6. R. Osman, P.L. L'Allier, N. Elgharib, and J.C. Tardif Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease Vasc Health Risk Manag 2 3 2006 221 237
7. T.J. Wang, P. Gona, and M.G. Larson Multiple biomarkers for the prediction of first major cardiovascular events and death N Engl J Med 355 25 2006 2631 2639
8. L. Retterstol, L. Eikvar, M. Bohn, A. Bakken, J. Erikssen, and K. Berg C-reactive protein predicts death in patients with previous premature myocardial infarction - a 10 year follow-up study Atherosclerosis 160 2 2002 433 440
9. C.L. Heslop, J.J. Frohlich, and J.S. Hill Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography J Am Coll Cardiol 55 11 2010 1102 1109
10. G. Brevetti, V. Schiano, and E. Laurenzano Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease Eur Heart J 29 2 2008 224 230
11. M.H. Criqui, L.A. Ho, J.O. Denenberg, P.M. Ridker, C.L. Wassel, and M.M. McDermott Biomarkers in peripheral arterial disease patients and near- and longer-term mortality J Vasc Surg 52 1 2010 85 90
12. H. Vidula, L. Tian, and K. Liu Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study Ann Intern Med 148 2 2008 85 93
13. T. Ganz Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes Infect Immun 55 3 1987 568 571
14. W.G. Rice, T. Ganz, J.M. Kinkade Jr., M.E. Selsted, R.I. Lehrer, and R.T. Parmley Defensin-rich dense granules of human neutrophils Blood 70 3 1987 757 765
15. A.V. Panyutich, E.A. Panyutich, V.A. Krapivin, E.A. Baturevich, and T. Ganz Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis J Lab Clin Med 122 2 1993 202 207
16. A.A. Higazi, I.I. Barghouti, and R. Abu-Much Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin J Biol Chem 270 16 1995 9472 9477
17. J.D. Morrisett The role of lipoprotein[a] in atherosclerosis Curr Atheroscler Rep 2 3 2000 243 250
18. K. Bdeir, W. Cane, and G. Canziani Defensin promotes the binding of lipoprotein(a) to vascular matrix Blood 94 6 1999 2007 2019
19. A.A. Higazi, T. Nassar, and T. Ganz The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis Blood 96 4 2000 1393 1398
20. T. Nassar, S. Akkawi, and R. Bar-Shavit Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor Blood 100 12 2002 4026 4032
21. P. Kougias, H. Chai, P.H. Lin, Q. Yao, A.B. Lumsden, and C. Chen Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis J Cell Mol Med 9 1 2005 3 10
22. E.S. Barnathan, P.N. Raghunath, J.E. Tomaszewski, T. Ganz, D.B. Cines, and A.a. Higazi Immunohistochemical localization of defensin in human coronary vessels Am J Pathol 150 3 1997 1009 1020
23. K. Quinn, M. Henriques, T. Parker, A.S. Slutsky, and H. Zhang Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases Am J Physiol Heart Circ Physiol 295 5 2008 H1817 H1824
24. M. Saraheimo, C. Forsblom, K. Pettersson-Fernholm, A. Flyvbjerg, P.H. Groop, and J. Frystyk Increased levels of alpha-defensin (- 1, - 2 and - 3) in type 1 diabetic patients with nephropathy Nephrol Dial Transplant 23 3 2008 914 918
25. H. Nassar, E. Lavi, and S. Akkawi alpha-Defensin: link between inflammation and atherosclerosis Atherosclerosis 194 2 2007 452 457
26. G. Joseph, L. Tarnow, and A.S. Astrup Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients J Clin Endocrinol Metab 93 4 2008 1470 1475
27. J.B. Joensen, S. Juul, E. Henneberg, G. Thomsen, L. Ostergaard, and J.S. Lindholt Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial Atherosclerosis 196 2 2008 937 942
28. A.T. Hirsch, Z.J. Haskal, and N.R. Hertzer ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) - summary of recommendation J Vasc Interv Radiol 17 9 2006 1383 1397
29. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 3 1988 837 845
30. M.M. McDermott, D. Green, and P. Greenland Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index Am J Cardiol 92 2 2003 194 199
31. S. Santos, T.W. Rooke, K.R. Bailey, J.P. McConnell, and I.J. Kullo Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index Vasc Med 9 3 2004 171 176
32. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 3 2003 499 511
33. T. Vainas, F.R. Stassen, and G. R. de C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events J Vasc Surg 42 2 2005 243 251
34. J.A. Beckman, O. Preis, P.M. Ridker, and M. Gerhard-Herman Comparison of usefulness of inflammatory markers in patients with versus without peripheral arterial disease in predicting adverse cardiovascular outcomes (myocardial infarction, stroke, and death) Am J Cardiol 96 10 2005 1374 1378
35. A. Lopez-Bermejo, B. Chico-Julia, and A. Castro Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans Arterioscler Thromb Vasc Biol 27 5 2007 1166 1171
36. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 1 2010 1 2